EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease

Aline Delva iD, Michel Koole, Kim Serdons, Guy Bormans, Mette Skinbjerg, Vinod Khetarpal, Longbin Liu, Jonathan Bard, Robert Doot, John H Warner, Swati Sathe, Cristina Sampaio und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07394-w ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Aline Delva und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, KU Leuven, Leuven, Belgium. aline.delva@uzleuven.be. Hauptthemen laut MEDLINE: Huntingtin Protein, Huntington Disease, Mutation, Positron-Emission Tomography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Fund for Scientific Research Flanders, CHDI Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: [11C]CHDI-00485180-R ([11C]CHDI-180R) is a novel PET radioligand developed to image aggregated mutant huntingtin (mHTT). Data from mouse models of Huntington's disease (HD) and biodistribution studies in healthy volunteers suggested that [11C]CHDI-180R is a promising candidate for in vivo determination of cerebral aggregated mHTT levels using PET. In the iMagemHTT study reported here, we investigated [11C]CHDI-180R kinetic properties and suitability to quantify aggregated mHTT in brains of people with HD (pwHD). METHODS: A total of 12 pwHD (53.7 ± 6.9y, 5 M/ 7 F, Shoulson-Fahn stage 2) and 12 healthy controls (HC; six young [26.8 ± 3.2y], 2 M/ 4 F; six age-matched [53.7 ± 6.1y],2 M/ 4 F) were included. We conducted dynamic 90 min [11C]CHDI-180R PET imaging with arterial sampling and radiometabolite quantification, and delineated volumes of interest (VOIs) using individual 3D T1-MRI. We calculated total distribution volumes (VT) using 2-compartment modelling (2TCM) as well as Logan graphical analysis and determined distribution volume ratios relative to cerebellum (DVRCBL). We applied partial volume correction, and assessed test-retest variability in pwHD. RESULTS: VT showed considerable intersubject variability among HC (VT(cortex) = 0.68 ± 0.22) and pwHD (VT(cortex) = 0.75 ± 0.26), without any regional significant differences between the groups. VT test-retest variability was high if test and retest scans were performed on the same day, but low (< 10%) if performed one week apart. DVRCBL showed significantly higher [11C]CHDI-180R relative binding in frontal, temporal, parietal, occipital and composite cortex VOIs (average increase 19.5 ± 6.1%) in pwHD than age-matched HC. CONCLUSION: [11C]CHDI-180R VT showed high intersubject variability and relatively low signal-to-background ratio. However, significant differences were found between pwHD and HC using cerebellum as pseudo-reference region. REGISTRATION: EudraCT 2018-001862-41 clinicaltrials.gov NCT03810898 https://clinicaltrials.gov/study/NCT03810898?term=NCT03810898&rank=1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntingtin ProteinHuntington DiseaseMutationPositron-Emission TomographyRadiopharmaceuticalsAdultFemaleHumansMaleMiddle AgedBrainCarbon RadioisotopesCase-Control StudiesLigandsTissue Distribution

Stichwörter der Autor:innen

Aggregated mutant huntingtinHuntington’s diseasePET imaging[11C]CHDI-180RmHTT

Substanzen

Carbon RadioisotopesHTT protein, humanHuntingtin ProteinLigandsRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Neurosciences, KU Leuven, Leuven, Belgium. aline.delva@uzleuven.be.
  • Department of Neurology, University Hospitals Leuven, Leuven, Belgium. aline.delva@uzleuven.be.
  • Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
  • Division of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • CHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.

ORCID-Profile: Aline Delva

Förderung

  • Fund for Scientific Research Flanders
  • CHDI Foundation

Zitieren

APA

Delva, A., Koole, M., Serdons, K., Bormans, G., Skinbjerg, M., Khetarpal, V., Liu, L., Bard, J., Doot, R., Warner, J. H., Sathe, S., Sampaio, C., Wood, A., Van Laere, K., & Vandenberghe, W. (2025). PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07394-w

Vancouver

Delva A, Koole M, Serdons K, Bormans G, Skinbjerg M, Khetarpal V, et al. PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07394-w

BibTeX
@article{Delva2025,
  author = {Delva, Aline and Koole, Michel and Serdons, Kim and Bormans, Guy and Skinbjerg, Mette and Khetarpal, Vinod and Liu, Longbin and Bard, Jonathan and Doot, Robert and Warner, John H and Sathe, Swati and Sampaio, Cristina and Wood, Andrew and Van Laere, Koen and Vandenberghe, Wim},
  title = {PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07394-w}
}
Kostenlos starten →